About Us: Funding

"Cell-cell Communication during melanoma progression"
Principal Investigator: Meenhard Herlyn
Agency: National Cancer Institute
Type: R01 (CA76674), Years 9-14, Period: December 5, 1997 to March 30, 2011.

"Human Melanoma: Etiology, Progression, and Therapy"
Principal Investigator: Meenhard Herlyn
Agency: National Cancer Institute
Type: P01-Program Project (CA25874), Years 25-29,
Period: April1, 2005 to March 31, 2010.
Subproject 1 (Meenhard Herlyn): "The microenvironment in melanoma development and progression".

"SPORE Skin Cancer"
Director: Meenhard Herlyn
Agency: National Cancer Institute
Type: P50-SPORE [Specialized Program of Research Excellence] (CA93372), Years 1-8, Period: Oct. 1, 2001 to June 30, 2010.
Project 3 (David Elder and Meenhard Herlyn, Co-Leaders): “Gene expression of experimentally induced human melanocytic lesions to define new markers for atypical nevi and primary melanomas from patients”.

"Mechanisms of esophageal carcinogenesis"
Principal Investigator: Anil Rustgi,
Co-Principal Investigator: Meenhard Herlyn
Type: P01-CA098101, Years 16-10, 2009-2014 Project 2 (Meenhard Herlyn): “The tumor microenvionment in human esophageal squamous cell carcinoma”.

"Targeted therapies in melanoma"
Principal Investigator: Meenhard Herlyn
Agency: National Cancer Institute
Type: P01-Program Project, CA 114046-02. 2008-2013.
Subproject 1 (Meenhard Herlyn): "Targeting the MAPK and PI3K pathways".

"3D skin models"
Principal Investigator: Meenhard Herlyn
Agency: National Institutes of Health
Type: RC1 ES018210-01. 10/1/09-6930/11

Core Activities:

  • ”Administrative Core A" for Melanoma Program Project, CA 25874, M. Herlyn P.I., 1990-2010.
  • ”Administrative Core A" for SPORE on Skin Cancer, CA93372, M. Herlyn, P.I., 2001-2009.
  • “Administrative Core A" for PO1 on Targeted Therapies in Melanoma, Pending, M. Herlyn, P.I.,
  • Administrative Core A" for SPORE on Skin Cancer, CA93372, M. Herlyn, P.I., 2001-2011.
  • "Cell Biology Core C" for Melanoma Program Project, CA 25874, M. Herlyn P.I., 1980-2010.
  • "Cell Biology Core C" for PO1 ‘Targeted therapy in melanoma”, 114046-02, 2008-2013.